Tom Brady spent two decades avoiding hits on the football field. His latest move puts him in the middle of a very different kind of contact sport: employer healthcare.
The NFL legend has backed a $200 million Series A round for eMed. The Miami-based digital health company uses AI to manage employee weight-loss programs, and the round pushes its valuation above $2 billion.
Who Else Is In the Round
Brady is not eMed’s only notable name. CEO Linda Yaccarino left her post running X last year to take eMed’s top job. She participated in the round alongside a group of high-profile investors.
The list includes AON Consulting, Paragon Biosciences founder Jeff Aronin and Valor Equity Partners CEO Antonio Gracias. It also includes 8VC founder Joe Lonsdale, Chicago Cubs chairman Tom Ricketts and restaurant executive R.J. Melman.
Brady holds the title of founding chief wellness officer at eMed, a role he says goes beyond lending his name.
“I believe eMed’s empathic agentic AI platform, combined with the strength of its people and partners, represents a true winning formula,” Brady said in a statement. “That conviction is why I’ve chosen to invest both my time… and my capital in the company.”
From COVID Tests to GLP-1 Coaching
eMed did not start out building AI health tools. The company launched in 2020 selling at-home COVID-19 tests, co-founded by Dr. Patrice Harris, a former American Medical Association president. It later pivoted toward weight management as demand for at-home testing faded.
Harris and eMed co-founder Dr. Michael Mina hosted a fireside chat with U.S. Surgeon General Dr. Vivek Murthy at eMerge Americas, Miami’s annual tech conference, back in 2022, well before the current AI-and-GLP-1 pivot.
Today eMed focuses on employer health benefits: access to GLP-1 medications, at-home blood testing and ongoing clinical support. Its programs are built to help employers manage the side effects that often come with GLP-1 treatment.
eMed reports 90% member adherence and average weight loss of 21 pounds among enrolled employees. The company has publicized those figures as its case for the model. They come from eMed’s own reporting, not an outside clinical review.
What the Money Is For
The new funding will go toward improving eMed’s agentic AI platform and preparing a new capitated care model, the company said. That model is designed to help employers expand GLP-1 access while controlling costs.
A capitated model means eMed would take on more financial risk for patient outcomes itself, rather than billing employers per service rendered. That is a different bet than the fee-for-service model most digital health startups run on.
Brady already runs a wellness business, TB12, which offers coaching, training guidance and recovery products. eMed gives him a second foothold in health and wellness, this time built around AI rather than sports recovery.
Yaccarino, for her part, is stepping into an industry built on regulatory approval and clinical trust. Advertiser relationships and platform virality do not translate here.
The Bigger Bet
eMed’s expansion depends on how well it delivers clinical support while meeting employer and patient needs, not just on star power. A celebrity investor can buy attention. It cannot buy compliance with FDA rules or convince a skeptical benefits manager to sign a contract.
Still, the funding gives Miami’s health-tech sector one of its highest-profile deals of the year. It is anchored by a company that started in the city selling COVID tests. It now runs an AI platform tied to some of the most in-demand drugs in medicine.
Whether eMed’s AI platform lives up to Brady’s “winning formula” language will show up in renewal rates with employers. It will not show up in headlines about who wrote the checks.